VirTech Bio Expands Scientific Advisory Board with Medical and Industry Leaders
We are happy to announce the expansion of our Scientific Advisory Board with two esteemed professionals and leaders in their fields: Aryeh Shander, M.D. and Kenneth Burhop, PH.D.
“We’re thrilled to have Dr. Shander and Dr. Burhop join our scientific advisory team,” said Col (R) Dallas Hack, MD, CEO of VirTech Bio. “Their deep expertise and far-reaching experience will be vital assets in advancing our mission.”
Aryeh Shander, M.D., FCCM, FCCP, is the Emeritus Chair, Department of Anesthesiology, Critical Care Medicine, Pain Management and Hyperbaric Medicine at Englewood Hospital and Medical Center in Englewood, NJ. He is an Adjunct Clinical Professor of Anesthesiology, Medicine, and Surgery at Icahn School of Medicine at Mount Sinai in New York City and Clinical Professor of Anesthesiology at Rutgers Medical School. Dr. Shander is also the Executive Medical Director of The Institute for Patient Blood Management and Bloodless Medicine and Surgery at Englewood Hospital. He is the co-founder and past president of the Society for the Advancement of Patient Blood Management (https://sabm.org) and is a Fellow of the American College of Critical Care Medicine and the American College of Chest Physicians.
Kenneth Burhop, PH.D. was Corporate Vice President and Chief Scientific Officer at Integra LiveSciences, responsible for setting Integra’s strategic scientific vision and roadmap. Dr. Burhop had direct responsibility for developing and leading the Clinical Operations, Medical Affairs, Medical Communications, Scientific Affairs, Regenerative R&D, Process Development and Exploratory R&D teams. Prior to joining Integra, Dr. Burhop served as Chief Scientific Officer at Sangart, Inc., and previously spent 24 years with Baxter Healthcare Corporation in a series of leadership roles including Vice President, R&D, Baxter Pharmaceutical Technologies, and Vice President, Global Scientific Lead for Baxter’s Medication Delivery Division, a business with over $4 billion in annual sales. Earlier, while at Baxter, Dr. Burhop served as the Director of Biological Sciences for the Hemoglobin Therapeutics Program and, following Baxter’s acquisition of Somatogen, he served as Vice President R&D for Baxter’s 2nd generation Recombinant Hemoglobin program located in Boulder, CO.
For more information about VirTech Bio and our HBOC solution OxyBridge™ contact us here: [email protected].